Portfolio Manager Factsheet

April 2019

Headwinds for the healthcare and biotechnology sectors this month included continued investor focus on drug pricing, rebate reform and “Medicare for All” proposals from several leading Democratic presidential candidates. We believe the prospects for a single-payer government-run healthcare system are highly unlikely.

Read more »

The Biotech Growth Trust PLC conducts its affairs so that its shares can be recommended by independent financial advisers (IFAs) to retail private investors. The shares are excluded from the Financial Conduct Authority's (FCA's) restrictions which apply to non-mainstream investment products because they are shares in a UK-listed investment trust.